US 11,718,880 B2
Marker and diagnosis method for noninvasive diagnosis of myocardial infarction
Chenggang Yang, Beijing (CN); and Shuguang Li, Beijing (CN)
Assigned to BEIJING MEDINTELL BIOMED CO., LTD, Beijing (CN)
Filed by BEIJING MEDINTELL BIOMED CO., LTD, Beijing (CN)
Filed on Dec. 15, 2020, as Appl. No. 17/247,534.
Application 17/247,534 is a continuation in part of application No. PCT/CN2019/094268, filed on Jul. 1, 2019.
Claims priority of application No. 201810715884.7 (CN), filed on Jul. 3, 2018; application No. 201810715888.5 (CN), filed on Jul. 3, 2018; application No. 201810717258.1 (CN), filed on Jul. 3, 2018; application No. 201810717286.3 (CN), filed on Jul. 3, 2018; application No. 201810718258.3 (CN), filed on Jul. 3, 2018; and application No. 201810718260.0 (CN), filed on Jul. 3, 2018.
Prior Publication US 2021/0115516 A1, Apr. 22, 2021
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/158 (2013.01)] 3 Claims
 
1. A method for analyzing a myocardial infarction-related gene, comprising the steps of:
(i) determining the expression level of a myocardial infarction-related gene in a biological sample from a subject, wherein the myocardial infarction-related gene is RAE1 and the biological sample is monocytes in the blood; and
(ii) comparing the expression level of RAE1 from step (i) to a normal control level of RAE1 in monocytes from a human that has not had MI,
wherein:
determining the expression level of a myocardial infarction-related gene in a biological sample from a subject comprises amplifying a fragment of an RAE1 transcript in the biological sample with the primers SEQ ID NO: 3 and SEQ ID NO: 4 and determining the expression level of RAE1 using chip detection or high throughput sequencing;
an increase in the expression level of RAE1 in the sample from the subject compared to the normal control level indicates that the subject has myocardial infarction;
and the subject is human.